Milan, 28(th)November 2011 - Pursuant to Article 2.6.2, paragraph 1, letter c)
of Borsa Italiana S.p.A.'s Regulation, Recordati S.p.A. hereby communicates the
calendar of corporate events for 2012.
9(th) February     Board of Directors' meeting to approve the 2011 preliminary
consolidated results.
8(th ) March           Board of Directors' meeting to approve the 2011
consolidated financial statements and the draft of Recordati S.p.A.'s 2011
financial statements.
19(th )April          Shareholders' General Meeting to approve the 2011
Financial Statements.
8(th ) May                              Board of Directors' meeting to approve
the 2012 first quarter interim management statement.
9(th) May               Presentation to financial analysts.
26(th )July                              Board of Directors' meeting to approve
the 2012 half-yearly report.
25(th )October      Board of Directors' meeting to approve the 2012 first nine
months' interim management statement.
Recordati, established in 1926, is a European pharmaceutical group, listed on
the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT
0003828271),with a total staff of over 2,800, dedicated to the research,
development, manufacturing and marketing of pharmaceuticals. It has headquarters
in Milan, Italy, operations in the main European countries, and a growing
presence in the new markets of Central and Eastern Europe. A European field
force of around 1,400 medical representatives promotes a wide range of
innovative pharmaceuticals, both proprietary and under license, in a number of
therapeutic areas including a specialized business dedicated to treatments for
rare diseases. Recordati's current and growing coverage of the European
pharmaceutical market makes it a partner of choice for new product licenses from
companies which do not have European marketing organizations. Recordati is
committed to the research and development of new drug entities within the
cardiovascular and urogenital therapeutic areas and of treatments for rare
diseases. Consolidated revenue for 2010 was € 728.1 million, operating income
was € 154.8 million and net income was € 108.6 million.
For further information:
Recordati website:Â www.recordati.com
Investor Relations                                       Media
Relations
Marianne Tatschke                                       Ketchum PR
(39)0248787393 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cristina Risciotti,
(39)0262411919, (39)3481343116,
e-mail:inver@recordati.it
cristian.risciotti@ketchum.it
                                      Marzia Ongaretti,
(39)0262411915,marzia.ongaretti@ketchum.it
RECORDATI: 2012 CORPORATE EVENTS’ CALENDAR :
http://hugin.info/143644/R/1567271/486837.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: RECORDATI via Thomson Reuters ONE
[HUG#1567271]
